4300 Hacienda Drive
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
Roche is the world leader in molecular and tissue diagnostics, and one of the leaders in clinical sequencing. As the innovation engine for Roche Diagnostics,Roche Molecular Solutions is translating cutting-edge science and innovation into clinical practice.
Visit our Career Blogs to see what our employees have to say about their life at Roche!
178 articles with Roche
Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors
Roche collaborates with Merck to develop companion diagnostic for use with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in advanced solid tumors with mismatch repair deficiency (dMMR)
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Susan G. Komen® Hails Findings from KATHERINE Trial Showing New Treatment Option That Reduces Breast Cancer Recurrence/Death Risk
Findings provide hope for long-term survival for HER2+ breast cancer patients
Collaboration includes the initial program utilizing Icagen's Drug Discovery Platform.
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
Roche subsidiary Genentech snaps up Jecure and its portfolio of preclinical NLRP3 inhibitors aimed at serious inflammatory diseases.
The VENTANA pan-TRK (EPR17341) Assay is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types
Daiichi Sankyo Company, Limited announced today that it has entered into an agreement with Roche to collaborate on the development of a new HER2 low companion diagnostic test.
Shanghai Roche Pharmaceuticals Ltd. and Ascletis BioScience Co., Ltd. jointly announce that starting from 1st Dec 2018, Ascletis and Roche will expand their partnership in viral Hepatitis.
Tesaro, located in Waltham, Mass., is rumored to be up for sale. The rumors caused shares to rocket as much as 39 percent on Friday, but it’s not the first time rumors have floated that the company might be on the auction block.
In Recognition of National Diabetes Awareness Month and Veteran's Day, Roche Honors the One in Four Veterans Living With Diabetes at iHeartCountry One Night For Our Military Concert
Raising Awareness for the More Than 30 Million Americans with Diabetes
Xofluza (baloxavir marboxil) was approved for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. The new medication has a novel mechanism of action that, Roche said, inhibits polymerase acidic endonuclease, an enzyme that is essential for the flu virus t...
Regeneron Pharmaceuticals’ Eylea (aflibercept) showed strongly positive data in a Phase III trial in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR). The trial met its 52-week primary endpoint and key secondary endpoints.
SQZ Biotech Expands Cell Therapy Partnership with Roche to Develop Antigen Presenting Cells for Immune-Oncology
Collaboration combines SQZ Biotech's novel cell therapy platform with Roche's cancer immunotherapy expertise
Ionis Enters New Collaboration with Partner to Develop IONIS-FB-L Rx for Complement-Mediated Diseases
Transaction valued at up to $760 million, including $75 million upfront payment, plus royalties up to 20%
Memorial Sloan Kettering's Chief Executive Officer Craig Thompson has resigned from the boards of directors at Merck and Charles River Labs as the cancer center continues to be scrutinized for its ties to the pharmaceutical industry.
Virion Therapeutics, LLC Announces its Inaugural Board of Directors and Scientific Advisory Board Members
Virion Therapeutics, LLC today announced the appointment of its inaugural Board of Directors and Scientific Advisory Board.
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
Dabbagh Poised to Lead Second Genome's Next Phase of Growth Focused on Therapeutic Drug Discovery and Development Derived from Microbiome Science.
Centrexion Therapeutics Appoints Andrew Partridge as Executive Vice President, Chief Commercial Officer
Centrexion Therapeutics Corporation today announced that Andrew Partridge has been appointed Executive Vice President, Chief Commercial Officer of the company.